Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of sorafenib plus gemcitabine versus sorafenib plus erlotinib in elderly or performance status 2 patients with advanced non-small cell lung cancer
2007-002941-20Phase 2Active
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Sorafenib + gemcitabine with Sorafenib + erlotinib (2 arms). Primary endpoint: Objective response evaluation. Started Jun 2007; status: active.
02
Drugs
sorafenibgemcitabineerlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-002941-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002941-20.